ArticleBritish journal of cancer2019

FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients.

Renata A Tassi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.